Estonia
Basilea Pharmaceutica Ltd (BPMUF) (Q2 2024) Earnings Call Transcript Highlights: Strong Revenue Growth and Strategic Developments
Revenue: CHF73.3 million from Cresemba and ZEVTERA.Operating Result: CHF9.3 million.Net Profit: CHF20.7 million.Cresemba In-Market Sales: USD489 million, a 24%